Companies › ScinnoHub Pharmaceutical
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Hematology, Genitourinary, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BT-114143 Injection | – | Phase 2 | Total Knee Arthroplasty; Abnormal Uterine Bleeding | Dec 2026 |
| SNH-119014 Pyruvate kinase red blood cell isozyme (PKR) agonist | PKLR | Phase 1 | Hemoglobinopathy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07169214 | BT-114143 Injection | Phase 1 | Abnormal Uterine Bleeding | Genitourinary | Sep 2025 |
| NCT07087262 | SNH-119014 | Phase 1 | Hemoglobinopathy | Hematology | Mar 2026 |
| NCT07127042 | BT-114143 Injection | Phase 2 | Total Knee Arthroplasty | Other | Dec 2026 |
Forma Therapeutics Agios Pharmaceuticals Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Shanghai Bao Pharmaceuticals Akebia Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.